INTRODUCTION
============

Acute pancreatitis is a commonly encountered problem in a hospital setting. Patients with moderate-to-severe acute pancreatitis may develop pancreatic fluid collections (PFCs) with or without necrosis. The majority of PFCs spontaneously resolve without the need for any intervention; however, persistently symptomatic PFCs require intervention. PFCs are classified using the Atlanta International Consensus Classification \[[@b1-ce-2019-116]\]. PFCs that persists for four weeks after an acute episode are classified as pancreatic pseudocysts (PPs) containing homogenous fluid or as walled off necrosis (WON) containing both solid and liquid material. Lately, endoscopic ultrasound (EUS)-assisted drainage of PFCs has been shown to be better than surgical drainage in terms of complications, technical success, and cost effectiveness \[[@b2-ce-2019-116]\]. EUS-guided transmural drainage and necrosectomy have become the standard treatment for patients with PFCs because of their safety and higher technical success rates than surgical and percutaneous methods \[[@b3-ce-2019-116],[@b4-ce-2019-116]\]. Lumen-apposing metal stents (LAMSs) are also successful in the management of PFCs and are utilized in a wide variety of procedures, including gallbladder drainage, gastrojejunostomy, and/or treatment of various gastrointestinal (GI) strictures \[[@b5-ce-2019-116]-[@b7-ce-2019-116]\]. Most studies evaluating LAMS for PFCs have been conducted in large academic centers with limited data from community hospitals. The objective of this study was to assess the efficacy and safety of LAMS in the treatment of PFCs in a community hospital.

MATERIALS AND METHODS
=====================

This study was a single center retrospective chart review of adult patients (ages 18 years and older) with acute pancreatitis who underwent an EUS-guided transmural PFC drainage using LAMS (AXIOS; Boston Scientific, Marlborough, MA, USA) at our institution during a period of three years (January 2014--November 2017). Indications for the procedure were symptoms that included mainly abdominal pain (either from gastric outlet or biliary obstruction), or signs of infection (fever, elevated white cell count) in patients with previously known PFCs that have not been resolved on conservative management. Exclusion criteria included patients aged less than 18 years, coagulopathy (international normalized ratio \>1.5), thrombocytopenia, or anatomy unsuitable for the procedure such as presence of blood vessels between the cyst and the tract wall or pseudocyst wall not in close proximity (\>1 cm) to the EUS probe. Data were collected by two investigators (RG and AC) after developing a standardized process to eliminate any subjective errors. We randomly checked the data of each investigator and any conflict was resolved by mutual consent. Our hospital's institutional review board approved the study.

Technique
---------

All patients underwent EUS-guided LAMS placement using the AXIOS stent (Boston Scientific). All procedures were performed by an experienced interventional endoscopist (MB) under general anesthesia as per the hospital protocol. PFCs were evaluated and drained under linear array echoendoscope before stent placement. Initially, only non-cautery-enhanced LAMS (Cold AXIOS; Boston Scientific) were available; however, later subjects underwent cautery-enhanced LAMS; (Hot AXIOS; Boston Scientific) placement. Non-cautery-enhanced AXIOS stent placement included direct visualization of PFC, using 19 G needle to puncture the collection, followed by passing the 0.035 inch guide wire through the needle and deployment of LAMS over guidewire under fluoroscopic and EUS guidance. Cautery-enhanced AXIOS stent placement involved puncturing the cyst wall using cautery tip under EUS guidance followed by deployment of LAMS immediately under EUS guidance. This process does not require the use of a guidewire and minimizes the time of exposure to radiation. During each procedure, a pancreatic fluid sample was aspirated and sent for analysis. The patients with positive fluid cultures from pancreatic aspirate were classified as infected pancreatic necrosis. The stent diameter (10 or 15 mm) was left at the discretion of endoscopist. The decision to administer antibiotics was based on patients' comorbidities and periprocedural morbidity. We used the recommended follow-up after LAMS placement for stent removal of 10--14 days, the time needed for the tract to mature. All the patients had scheduled follow-up at two to four weeks based on interval cross-sectional imaging. Patients who demonstrated significant improvement were followed up earlier than patients with slow improvement on imaging. All LAMS were removed with grasping forceps.

We collected data on age, sex, date of stent placement, cause of pancreatitis, type of fluid collection, infection, size of stent (mm×mm), location, technical success, clinical success, drainage site (transgastric or transduodenal), type of access (hot or cold AXIOS), proximal release of flange (direct or endoscopic with fluoroscopic visualization), length of procedure (min), sedation type, periprocedural antibiotics and major adverse events (bleeding, stent migration or perforation), number of required subsequent necrosectomies, date of stent removal, date of last/most recent imaging, complete resolution of PFC, and date of last follow-up. All adverse events were graded based on the American Society of Endoscopy lexicon guidelines \[[@b8-ce-2019-116]\]. We did not collect data on coaxially or subsequently placed pigtail stents.

The primary outcome was the rate of clinical success (resolution of PFC, based on repeated radiological imaging) with technical success and adverse events constituted the secondary outcome. Patients were divided into two groups, those with PPs and those with WON. PFCs were classified after reviewing both the imaging (typically computed tomography \[CT\] scans) and EUS reports based on the revised Atlanta classification. Patients who had WON underwent direct endoscopic necrosectomies.

Technical success was defined as successful placement of the stent with subsequent observed drainage of the pancreatic fluid in the GI tract. Clinical success was defined as resolution of PFCs along with symptoms based on repeated imaging (EUS or CT scan). Partial resolution was defined as at least 75% decrease in size of PFCs on repeat imaging.

Major adverse events were periprocedural (within one day) bleeding, stent migration before removal or bowel perforation. All the adverse events were graded based on the American Society of Endoscopy lexicon guidelines. The follow-up period of adverse events was until the stent removal.

Statistical analysis
--------------------

Continuous variables were described using the mean and standard deviation or median and range. Categorical variables were reported as frequency distributions. Means were compared using Student's *t*-test. Mann-Whitney *U*-test was used for data that did not follow a normal distribution. The association between categorical variables was assessed using chi-squared analysis. Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 25 (IBM Co., Armonk, NY, USA). A *p*-value of ≤0.05 was considered statistically significant.

RESULTS
=======

Demographic and clinical characteristics
----------------------------------------

We included 27 patients who underwent LAMS placement from January 2014 to November 2017. Twelve patients (44%) had PPs while fifteen (56%) had WON. The mean age of the patients was 54.1±16.5 years; twelve (44.4%) of which were male. The most common etiology of pancreatitis was alcohol (44.4%) followed by idiopathic causes (29.6%), presence of gallstones (22.2%), and cystic fibrosis (3.7%). There were no differences in etiologies between patients with PPs and WON. All the patients with PPs were drained as day care procedure whereas infected necrosis patients were treated as inpatient procedure as part of their acute care ([Table 1](#t1-ce-2019-116){ref-type="table"}).

Pancreatic fluid collections characteristics
--------------------------------------------

The maximum diameter of PFCs ranged from 3 to 21 cm with a mean of 9.7±5.0 cm. WONs were noted to be larger than PPs (11.3±5.1 vs. 7.8±4.1 respectively, *p*=0.07).

The majority of PFCs were located in the pancreatic body, while the second most common site was the pancreatic tail. Only two patients had pancreatic head involvement ([Table 1](#t1-ce-2019-116){ref-type="table"}).

Procedure details
-----------------

The mean procedure duration was 26±12.5 minutes; the longest procedure took 60 minutes. All patients underwent general anesthesia. Almost all procedures (96.3%) were performed using a transgastric approach while only one patient had a trasduodenal access. The hot AXIOS delivery system was used in 23 (85.2%) patients while the remaining 4 (14.8%) patients underwent treatment with the cold AXIOS delivery system. Two different stent sizes were used: 10×10 mm and 15 mm wide × 10 mm long (44.4% and 55.6%, respectively). Nineteen (70.4%) patients received periprocedural antibiotics.

The data showed no difference between patients with PPs and WON in terms of procedure duration, drainage site, type of delivery system used, stent size, or use of antibiotics. No statistical test could be performed because of the small sample size ([Table 2](#t2-ce-2019-116){ref-type="table"}).

Outcomes
--------

The median number of days from placement to removal was 31 days (range, 11--260 days). No major adverse events were reported. Technical success was achieved in all patients, whereas clinical success was observed in 22 of 27 patients (81.5%). There were no occurrences of procedure-related bleeding, infection, obstruction, or clinically significant migration. There was one patient with asymptomatic stent migration on follow-up endoscopy. Patients with PPs and WONs had similar success rates, 83.3% and 80%, respectively. None of the patients with PPs required any subsequent interventions, whereas almost half of those with WONs (47.7%) underwent at least one subsequent necrosectomy. Out of 15 patients with WON, 7 had infected necrosis (cultures positive from pancreatic fluid aspirate) who required subsequent intervention. The number of subsequent interventions ranged from 1 to 5 with their clinical response guiding the need for re-intervention. Median time interval after the procedure was 2 weeks.

Ten out of twelve (83.3%) patients with PPs had complete resolution while the remaining two patients did not have data available. We only used data on technical success and immediate adverse events for patients who did not follow-up. In terms of WON, 10 of 15 cases (66.7%) resolved completely, 2 (13.3%) had partial resolution, and 3 (20%) did not resolve. All our patients achieved symptom control despite residual PFCs on follow-up imaging, and none of the patients required percutaneous drain or surgical intervention ([Table 3](#t3-ce-2019-116){ref-type="table"}).

DISCUSSION
==========

Our study demonstrates that LAMS is safe and effective for PFC drainage, even in a community hospital setting. Our findings are similar to those from large academic tertiary centers \[[@b9-ce-2019-116]\]. LAMS has streamlined the endoscopic treatment of PFCs because of the ease of use and availability. The placement of LAMS was effective in 100% of the cases without any immediate post-procedural complications with 81.5% of patients achieving clinical success. Although there are multiple studies demonstrating the efficacy of this approach, our study is the first to evaluate it in a community hospital setting, which demonstrates the wide applicability of this procedure.

The standard of care for the management of PFCs (including PPs and WON), adjacent to the gastric and duodenal lumen, involves internal drainage under EUS guidance. Endoscopic drainage of PFCs is highly preferred over alternative percutaneous or invasive surgical drainage, which is associated with high morbidity and mortality. Endoscopic drainage of PFCs is accomplished by creation of a controlled fistulous tract under EUS guidance, subsequently followed by the insertion of plastic biliary stents or fully covered self-expandable metal stents (FCSEMSs) for continued drainage. Transmural treatment of PFCs involves internal drainage of the collection into the bowel lumen. To perform endoscopic drainage, the fluid collection should be of reasonable size (generally \>3 cm) and have a well-defined wall, with part of the wall of the fluid collection adherent to the GI tract lumen. Accessing the fluid collection is performed under EUS guidance, which allows for evaluation of the distance between the fluid collection and GI wall, detection of wall adherence, and identification of vessels that may be interposed between the two lumens \[[@b10-ce-2019-116]\].

In the past, the procedure required guidewire insertion into the fluid collection, dilation to enlarge the transmural tract creating an endoscopic fistula, and placement of multiple plastic stents for drainage \[[@b10-ce-2019-116]\]. The success of the procedure using plastic stents is affected by the type of PFCs and the size and number of plastic stents placed. Collections that are thick, necrotic, or infected may not adequately drain through plastic stents and may become secondarily infected after occlusion \[[@b11-ce-2019-116]\].

More recently, a single step catheter has been used to accomplish drainage of these fluid collections under endosonographic guidance. FCSEMS with an electrocautery-enhanced delivery system have significantly larger lumens than those of plastic stents, and help create a lumen-to-lumen anastomosis that can keep the lumens in apposition to each other \[[@b12-ce-2019-116]\]. Moreover, placement of LAMS also provides direct access to the cavity for further debridement with anchoring flanges preventing dislodgement.

The overall technical success rate exceeds 90% in the majority of published literature with complication rates around 10%--15% \[[@b9-ce-2019-116],[@b13-ce-2019-116],[@b14-ce-2019-116]\].

The role of LAMS in the drainage of PFCs has been well established in multiple studies from large academic tertiary centers \[[@b9-ce-2019-116],[@b11-ce-2019-116],[@b14-ce-2019-116],[@b15-ce-2019-116]\]. Because the efficacy of LAMS in community hospital settings has not been studied, our goal was to assess our experience in our large urban community teaching hospital. Our study demonstrates that LAMS can be used effectively and safely in a community hospital, provided that an operator with sufficient expertise is available. We did not collect data on coaxially placed pigtail stents, and pigtail stent placement was left at the discretion of the endoscopist. Technical and clinical success rates were 100% and 81.5%, respectively, without any immediate periprocedural complications. Interestingly, time to removal of LAMS appears to be shorter in patients with WON compared to those with PP. The likely reason of this finding is patients with WON required subsequent necrosectomies and closer follow-ups whereas patients with pseudocysts did not require subsequent interventions.

A recent study on 250 patients reported high rates of migration in patients undergoing LAMS placement for all indications. The rate of migration was 8.6% within the first three months for all indications, which increased to 48.5% at 12 months for PFCs compared to other indications that had a low (6.3%) rate of migration \[[@b16-ce-2019-116]\]. The study also found coaxially placed pigtail stents to be independently associated with an increased risk of migration. There were low rates of bleeding (5.4%) related to stent placement, with most cases of bleeding occurring within one week of stent placement. Moreover, there were increased rates of bleeding with cold AXIOS (10) compared to hot AXIOS (3). Interestingly, three out of five patients with PFCs had delayed bleeding compared to other indications that had early bleeding \[[@b16-ce-2019-116]\]. Our data are consistent with results of previous studies with a low rate of migration (0%--19%) \[[@b17-ce-2019-116]-[@b19-ce-2019-116]\]. The only migration in our study group was asymptomatic without any bleeding or obstruction.

LAMS with coaxially placed pigtail stents for PP drainage has been reported to be associated with low rates of infection compared to placement of LAMS alone (0% vs. 17%) \[[@b20-ce-2019-116]\]. Another study reported that placement of coaxial placed pigtail stent within LAMS was associated with a low risk of bleeding and infection as compared to placement of LAMS alone; however, most patients in the LAMS only group utilized the cold AXIOS technique which could have confounded their results.15 A recent study reported LAMS (92%) to be more effective as compared to plastic stents (84%). However, LAMS were obviously more expensive with an incremental cost effectiveness ratio favoring LAMS per additional patient successfully treated for treatment of WON \[[@b21-ce-2019-116]\].

Our study has several limitations. First, it was a retrospective study with its inherent limitations. Second, there was no standardized follow-up for our patients. Third, endoscopies were performed by a single person, that might not reflect the true incidence of success in a large setting; however, this kind of expertise is not widely available and most patients are referred to tertiary centers from community hospitals. We also had variable rates of follow-up in our study with the longest follow-up of 385 days in WON and 346 days in PP group. The follow-up was dependent on the clinical visit and based on individual case. Many of our patients are still being followed up but due to small sample size and study completion, we could not factor ongoing follow-up. Furthermore, we did not separate patients with coaxially placed pigtail stents and subsequent placed pigtail stents for necrosectomies, which might have affected the outcomes.

Despite these limitations, our study has several strengths. Our study adds to the literature about the safety of the procedure and calls for wide acceptance of this minimally invasive procedure. We demonstrated for the first time that this procedure can be safely performed in community hospitals with outcomes as good as in academic centers.

In conclusion, our study reiterates the safety and efficacy of LAMS in treatment of PFCs even in community hospital setting and could widely provide the availability of expertise and institutional support. We also believe that advanced endoscopists at community hospitals can undergo training for this procedure by performing at least 25 procedures under the guidance of an experienced operator.
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###### 

Patient and Pancreatic Fluid Collection Characteristics of Patients Who Underwent Pancreatic Fluid Collection Drainage

                                   PFCs, *n*=27   Pseudocysts, *n*=12 (Group 1)   Won, *n*=15 (Group 2)   *p*-value (Group 1 vs. Group 2)
  -------------------------------- -------------- ------------------------------- ----------------------- ---------------------------------
  Sex, *n* (%)                                                                                            
   Male                                           6 (50.0)                        6 (40.0)                0.60
   Female                                         6 (50.0)                        9 (60.0)                
  Age, mean±SD (yr)                54.1±16.5      52.6±15.9                       55.3±17.4               0.68
  Pancreatitis etiology, *n* (%)                                                                          
   Alcohol                         12 (44.4)      5 (41.7)                        7 (46.7)                
   Cystic fibrosis                 1 (3.7)        1 (8.3)                         0 (0.0)                 
   Gallstones                      6 (22.2)       3 (25.0)                        3 (20.0)                
   Idiopathic                      8 (29.6)       3 (25.0)                        5 (33.3)                
  Infected PFC, *n* (%)                                                                                   
   No                              20 (74.1)      12 (100)                        8 (53.3)                
   Yes                             7 (25.9)       0 (0.0)                         7 (46.7)                
  Location, *n* (%)                                                                                       
   Body                            11 (40.7)      5 (41.7)                        6 (40.0)                
   Head                            1 (3.7)        1 (8.3)                         0 (0.0)                 
   Tail                            2 (7.4)        2 (16.7)                        0 (0.0)                 
   Body/head                       1 (3.7)        1 (8.3)                         0 (0.0)                 
   Body/tail                       12 (44.4)      3 (25.0)                        9 (60.0)                
  Maximum PFC diameter, mm±SD      97.2±49.7      77.8±41.5                       112.7±51.1              0.07

PFC, pancreatic fluid collection; SD, standard deviation; WON, walled off necrosis.

###### 

Procedural and Periprocedural Details of Patients Who Underwent Pancreatic Fluid Collection Drainage Using Lumen-Apposing Metal Stent

                                                      PFCs, *n*=27   Pseudocysts, *n*=12 (Group 1)   WON , *n*=15 (Group 2)   *p*-value (Group 1 vs. Group 2)
  --------------------------------------------------- -------------- ------------------------------- ------------------------ ---------------------------------
  Duration of procedure, min±SD                       26±12.5        27±14.4                         25.2±11.1                0.72
  Drainage site                                                                                                               
   Transduodenal                                      1 (3.7)        1 (8.3)                         0 (0.0)                  
   Transgastric                                       26 (96.3)      11 (91.7)                       15 (100.0)               
  Type of access                                                                                                              
   Cold AXIOS                                         4 (14.8)       1 (8.3)                         3 (20)                   0.40
   Hot AXIOS                                          23 (85.2)      11 (91.7)                       12 (80)                  
  Stent Size                                                                                                                  
   10×10                                              12 (44.4)      7 (58.3)                        5 (33.3)                 0.19
   15×10                                              15 (55.6)      5 (41.7)                        10 (66.7)                
  Proximal release of flanges                                                                                                 
   Direct visualization (hot)                         23 (85.2)      11 (91.7)                       12 (80.0)                0.40
   Endoscopic and fluoroscopic visualization (cold)   4 (14.8)       1 (8.3)                         3 (20.0)                 
  Sedation used                                                                                                               
   General anesthesia                                 27 (100)       12 (100)                        15 (100)                 
  Antibiotic used                                                                                                             
   Yes                                                19 (70.4)      7 (58.3)                        12 (80)                  0.22
   No                                                 8 (29.6)       5 (41.7)                        3 (20)                   

PFC, pancreatic fluid collection; SD, standard deviation; WON, walled off necrosis.

###### 

Follow-Up/Outcomes of Patients Who Underwent Pancreatic Fluid Collection Drainage

                                                                                          PFCs, *n*=27     Pseudocysts, *n*=12 (Group 1)   WON , *n*=15 (Group 2)   *p*-value (Group 1 vs. Group 2)
  --------------------------------------------------------------------------------------- ---------------- ------------------------------- ------------------------ ---------------------------------
  Technical success                                                                                                                                                 
   Yes                                                                                    27 (100)         12 (100)                        15 (100)                 
  Clinical success                                                                                                                                                  
   Yes                                                                                    22 (81.5)        10 (83.3)                       12 (80.0)                
   No                                                                                     2 (7.4)          0 (0.0)                         2 (13.3)                 
   Lost to follow-up                                                                      2 (7.4)          2 (16.7)                        0 (0.0)                  
   Being followed up currently                                                            1 (3.7)          0 (0.0)                         1 (6.7)                  
  Major adverse events                                                                                                                                              
   No                                                                                     27 (100)         12 (100)                        15 (100)                 
  Complete resolution of PFC                                                                                                                                        
   Yes                                                                                    20 (74)          10 (83.3)                       10 (66.7)                
   Resolving                                                                              2 (7.4)          0 (0.0)                         2 (13.3)                 
   No                                                                                     3 (11.1)         0 (0.0)                         3 (20.0)                 
   Missing data                                                                           2 (7.4)          2 (16.7)                        0 (0.0)                  
  Number of required subsequent necrosectomies                                                                                                                      
   0                                                                                      20 (74.1)        12 (100.0)                      8 (53.3)                 
   ≥1                                                                                     7 (25.9)         0 (0.0)                         7 (47.7)                 
  Time to removal, days, median \[range\]^[a)](#tfn1-ce-2019-116){ref-type="table-fn"}^   31 \[11--260\]   43.5 \[11--260\]                28.0 \[12--55\]          0.28
  Removal to follow-up, median \[range\]^[a)](#tfn1-ce-2019-116){ref-type="table-fn"}^    52 \[0--385\]    29.5 \[0--346\]                 52 \[0--385\]            0.28

PFC, pancreatic fluid collection; WON, walled off necrosis.

Except two cases lost to follow-up.
